glp-1 agonists for diabetes Targeting GLP-1, GIP & GCG in Obesity and Type 2 Research Glucagon-like peptide-1 (GLP-1) receptor agonists
Description
Funding This work was supported by grants from the Chung Shan Medical University Hospital (CSH-2020-C-016)
Ulie, 2025)
doi: 10.1111/dom.12932
The burden of DM is compounded by common comorbidities such as atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD), which affect nearly one-third of individuals with DM [1, 2]
most companies offer monthly subscriptions to their products (a six-month supply of Lemmes pills, for example, costs $378)
